391 related articles for article (PubMed ID: 23536478)
1. Variations in circulating sex steroid levels in metastatic prostate cancer patients with combined androgen blockade: observation and implication.
Qin X; Zhang H; Ye D; Yao X; Zhang S; Dai B
Andrology; 2013 May; 1(3):512-6. PubMed ID: 23536478
[TBL] [Abstract][Full Text] [Related]
2. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
4. Hormonal therapy of prostate cancer.
Labrie F
Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
[TBL] [Abstract][Full Text] [Related]
5. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
6. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
[TBL] [Abstract][Full Text] [Related]
7. Intermittent complete androgen blockade in metastatic prostate cancer.
Rambeaud JJ
Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
[TBL] [Abstract][Full Text] [Related]
8. Serum testosterone level to predict the efficacy of sequential use of antiandrogens as second-line treatment following androgen deprivation monotherapy in patients with castration-resistant prostate cancer.
Hashimoto K; Masumori N; Hashimoto J; Takayanagi A; Fukuta F; Tsukamoto T
Jpn J Clin Oncol; 2011 Mar; 41(3):405-10. PubMed ID: 20947624
[TBL] [Abstract][Full Text] [Related]
9. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
Perachino M; Cavalli V; Bravi F
BJU Int; 2010 Mar; 105(5):648-51. PubMed ID: 19747358
[TBL] [Abstract][Full Text] [Related]
10. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
[TBL] [Abstract][Full Text] [Related]
11. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
13. Innovative approaches to the hormonal treatment of advanced prostate cancer.
Trachtenberg J
Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer.
Shiota M; Takeuchi A; Sugimoto M; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
Anticancer Res; 2015 Dec; 35(12):6925-32. PubMed ID: 26637918
[TBL] [Abstract][Full Text] [Related]
15. Role of testosterone in managing advanced prostate cancer.
Rove KO; Debruyne FM; Djavan B; Gomella LG; Koul HK; Lucia MS; Petrylak DP; Shore ND; Stone NN; Crawford ED
Urology; 2012 Oct; 80(4):754-62. PubMed ID: 22795376
[TBL] [Abstract][Full Text] [Related]
16. Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?
Mottet N; Lucas C; Sene E; Avances C; Maubach L; Wolff JM
Urol Int; 2005; 75(3):204-8. PubMed ID: 16215305
[TBL] [Abstract][Full Text] [Related]
17. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
18. Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy.
Tunn UW; Canepa G; Kochanowsky A; Kienle E
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):296-302. PubMed ID: 22733160
[TBL] [Abstract][Full Text] [Related]
19. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy.
Morote J; Planas J; Salvador C; Raventós CX; Catalán R; Reventós J
BJU Int; 2009 Feb; 103(3):332-5; discussion 335. PubMed ID: 19007366
[TBL] [Abstract][Full Text] [Related]
20. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]